Samsung Bioepis
Samsung Bioepis develops biosimilars of trastuzumab, bevacizumab and other antibodies, made by its parent Samsung Biologics at Songdo.
Overview
Samsung Bioepis was founded in 2012 as a joint venture between Samsung Biologics and Biogen and became wholly owned by Samsung Biologics in 2022. It develops biosimilars, among them trastuzumab (Ontruzant) and bevacizumab (Aybintio), which are manufactured at Samsung Biologics' Songdo plants and sold with partners in Europe and the United States.
Scorecard
All companies- approved products +12
- targets +4
- modalities +2
- regions +7
- registry trials +30
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
Similar pages
not linked directly; found by shared links- CompanySartorius
Shares Antibody manufacturing (CHO bioprocessing) and the tag manufacturing-wave.
- TechnologyDownstream purification (Protein A capture, viral clearance, polishing)
Shares Antibody manufacturing (CHO bioprocessing), Biosimilar manufacturing and comparability, Trastuzumab, Bevacizumab and the tag manufacturing-wave.
- TechnologyGMP, inspections, Form 483s and warning letters
Shares Antibody manufacturing (CHO bioprocessing), Biosimilar manufacturing and comparability and the tag manufacturing-wave.
- TechnologySingle-use bioprocessing systems
Shares Antibody manufacturing (CHO bioprocessing) and the tag manufacturing-wave.
- TechnologyThe ADC supply chain (antibody, payload-linker, conjugation, fill)
Shares Antibody manufacturing (CHO bioprocessing) and the tag manufacturing-wave.
- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Trastuzumab, Bevacizumab, Colorectal cancer.
- TrialTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Shares Trastuzumab, Colorectal cancer.
- TrialHER2CLIMB-05
Shares Trastuzumab, HER2-positive breast cancer.